Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

The en­zyme en­gi­neer­ing spe­cial­ists at Codex­is are giv­ing up on mak­ing their own ther­a­pies, in­stead fo­cus­ing on sell­ing its tech­nolo­gies and ser­vices to cus­tomers — in­clud­ing process­es to sup­port com­mer­cial-scale man­u­fac­tur­ing of RNAi drugs.

As a re­sult, the com­pa­ny said it will let 25% of its staff go while con­sol­i­dat­ing its San Car­los, CA fa­cil­i­ty to its Red­wood City, CA head­quar­ters. It had 248 em­ploy­ees, both full-time and part-time, at the end of 2022.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN